Acrodose™ Platelet: Whole Blood Derived Platelets, Pooled
 Safety | Efficiency | Availability
Acrodose Systems make use of the abundant supply of whole blood platelets that are more readily available than apheresis platelets. As a result, blood centers can expect increased product availability, fewer product shortages, and less need to import. An Acrodose Platelet offers a safe, efficient, and a readily-available alternative in platelet transfusion safety.
An Acrodose Platelet is a new platelet product that provides both blood centers and hospitals with a low-cost alternative to traditional whole blood derived (WBD) platests, as well as apheresis platelets.
Acrodose Platelets are:
- Not random donor platelets. An Acrodose Platelet is transfusion-ready for the hospital, as it is pooled, leukoreduced, ABO matched, and culture based tested for bacteria while also meeting AABB Interim Standard 5.1.5.1.1 for bacteria detection.
- And they are not a single donor platelet. An Acrodose Platelet provides a therapeutic dose of platelets equivalent to a single donor platelet, but typically at a lower cost.
|
|
 |
Platelet Supply vs. Increasing Demand
Today many healthcare organizations are facing growing pressure to reduce costs, while maintaining or increasing their platelet supply due to the increasing demand for platelets. In many parts of the USA, apheresis platelets have become the standard of care. However, reliance on costly apheresis platelets has led to product shortages, especially during periods such as weekends and holidays. Further compounding the problem are continuing restrictions on donor acceptance*, making it even more difficult to maintain the blood supply.
*AABB Bulletin 06-07: AABB issued guidelines restricting use of previously pregnant female donors from donating "high plasma volume" blood products such as apheresis platelets. Whole blood-derived platelets are defined by the most recent AABB bulletin as a "lower plasma volume component" and "the per-unit risk attributed to antibody-mediated TRALI from [this] component appears to be significantly lower."
The Acrodose Platelet - A New Approach to Platelet Transfusion Therapy
Acrodose Platelets are a therapeutic dose of whole blood derived platelets that are equivalent to apheresis platelets, and made available through a pooling technology called Acrodose Systems. This innovative product consists of ABO-matched whole blood-derived platelets that are leukoreduced, pooled, and bacteria tested. Discover how an Acrodose Platelet can make a difference by satisfying your platelet availability needs, providing opportunities for growth, and improving your bottom line.
- Significantly increases platelet availability: An Acrodose Platelet enables blood centers to tap into the abundant, but often discarded resource of whole blood platelets while providing the equivalent clinical benefits of an apheresis platelet.
- Provides blood center growth opportunities: Because of their abundant supply and low cost, the production of a therapeutic dose of whole blood-derived platelets can eliminate the reliance on platelet importing due to product shortages, and serve as an effective counter-measure to the donor restrictions outlined in AABB Bulletin 06-07.
- Blood centers go from importers to exporters: Blood centers that are able to adequately satisfy their local platelet requirements may find that upon adopting Acrodose Systems, they are able to export their excess platelets, providing an untapped growth opportunity for the blood center.
- Improves hospital inventory management: Acrodose Platelets may be stored until outdate, allowing return back to inventory if not transfused.
- Lowers hospital handling costs: An Acrodose Platelet is received at the hospital pre-pooled and tested via an FDA market-cleared device for bacteria detection. Hospitals will no longer have to test their whole blood platelets and can expect to receive a transfusion ready product that meets AABB Interim Standard 5.1.5.1.1. Learn more...
Try the Acrodose System Financial Calculator
Directly tied to the benefit of greater platelet availability is the opportunity for lower costs, increased revenues and greater margins. Both blood centers and hospitals can expect to benefit financially from an Acrodose Platelet. Learn how.
- For the blood center: Compare costs, revenues, and margins for manufacturing and selling an Acrodose Platelet vs. an apheresis platelet. The blood center cost model also provides an estimate of lost product and revenues due to the loss of female donors as a result of the AABB Bulletin on TRALI, and how Acrodose may be able to offset some or all of that lost product and revenue.
- For the hospital: The Acrodose Cost Calculator for the hospital looks at the costs associated with platelet filtration and pooling, as well as lost product (due to the 4-hour expiration for traditionally pooled platelets), and provides potential cost savings that may result by switching to an Acrodose Platelet.
Scientific and Technical Report: Platelets Likely Lose Efficacy When Stored From 5 to 7 Days
Three studies examining 5- vs. 7-day platelets are available. All suggest, by their surrogates, that platelets stored for 5 days are more efficacious than those stored for 7 days.
Read the report...
Scientific and Technical Report: Pool and Store Platelets - Augmenting Quality Platelet Supply To Meet Transfusion Requirements
In an effort to meet platelet transfusion requirements, platelets pooled prior to storage (referred to as pool and store [P&S] platelets) may prove to be an acceptable alternative when apheresis product is not available. In order to make an informed decision regarding the comparability of buffy coat (BC) or whole blood-derived (WB-d) P&S platelets with apheresis product, these four questions are presented and discussed:
- Can the quality of apheresis or single donor platelets (SDP) be considered comparable to WB-d or BC platelets that are pooled prior to storage?
- Can platelet products be pooled to consistently provide platelet counts that are comparable to those found in an SDP product?
- Is donor exposure, to mediators of morbidity inherent in any one donor, increased by pooling to the point where it causes significant concern?
- Can quality bacteria detection be applied to ensure the safety of the platelet product?
Read the report...
Complementary Products
Using a platform of complementary products, blood collection facilities are able to produce a therapeutic dose of platelets that are pooled, leukoreduced, ABO matched, and bacteria tested with culture based detection methods – in other words, an
Acrodose Platelet. Read more about:
For the full story, go to A New Platform for Platelet Transfusion Safety.